Pfizer Filing Shows 70 Percent Decline in COVID Vaccine Revenue

Published on February 29, 2024

Vaccine-maker Pfizer Inc., in a filing to the U.S. Securities Exchange Commission, wrote that its COVID-19 vaccine revenue is down 70 percent in 2023. “Declines largely driven by lower contracted deliveries and demand in international markets and lower U.S. government contracted deliveries, due to transition to new variant vaccines in most markets and the transition to traditional U.S. commercial market sales which began in September 2023,” the company wrote in the filing, which was drafted last week. Global revenues for the vaccine hit $11.2 billion for last year, said the filing. However, that’s a far cry from 2022’s numbers when the company’s vaccine revenue stood at $37 billion for the year, or down about 70 percent....